RADIOPHARM THERANOSTICS LIMITED (RAD)

Latest AI Signal: BUY
Status: NEW
Days Old: 3

Confidence: 45%

Date: 18-05-2026

Price: $0.021

Last Price: $0.021

Post-Signal Peak Price: $0.021

Latest  RADIOPHARM THERANOSTICS LIMITED(RAD)   News

03 Nov 2025, 08:06 PM

RADX: Program and Financial Updates

By John Vandermosten, CFA NASDAQ:RADX READ THE FULL RADX RESEARCH REPORT On October 28th, Radiopharm Theranostics Limited (NASDAQ:RADX) announced its first quarter cash flows in its Activities and Cash Flow Report, disclosing a cash balance of A$19.0 million as of September 30th, 2025. During the

21 Jun 2022, 10:43 PM

UPDATE -- Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on June 23, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional Investors NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will h

27 Apr 2022, 11:00 PM

Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV. Event website: www.PlanetMicroCapShowcase.com The Planet Mi

16 Feb 2022, 01:00 AM

Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022

Presenting Companies to Host 25 Minute Presentations Followed by Question-and-Answer Session; Conference Open to all Retail and Institutional Investors NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will h

Chart available once enough post-signal price data is available.

BUY Confidence Low

AI Confidence - 45 % model confidence

Business Overview

Radiopharm Theranostics Limited is a clinical-stage radiopharmaceutical company focused on developing and commercializing targeted diagnostic and therapeutic agents for cancer treatment. The company operates in the niche but growing market of precision oncology, leveraging novel radiolabeled compounds to improve cancer detection and therapy, positioning itself as an innovative player in the theranostics sector.

Financial Analysis

Cash Flow	Weak
Debt	Unknown
Profitability	Weak
Revenue Trend	Unknown

Technical Analysis

Trend	Bullish
Momentum	Moderate
RSI Signal	Neutral
Support Level	$ 0.0180
Resistance Level	$ 0.0250

Valuation

Valuation - Undervalued

The stock trades at a low price point reflecting early-stage risk but offers significant upside potential given its innovative pipeline and market opportunity.

Catalysts

• Upcoming clinical trial results or regulatory approvals

• Strategic partnerships or licensing deals

• Positive market reception of initial product launches

Recommendation

Action - Buy

Timeframe - Medium Term

Radiopharm Theranostics offers a compelling risk-reward profile driven by its innovative cancer diagnostic and therapeutic pipeline. While financials are weak and risks remain high, upcoming catalysts could unlock significant value, making it an attractive buy for medium-term investors.